Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;100(5):758-769.
doi: 10.1002/ajh.27628. Epub 2025 Feb 8.

Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies

Jayastu Senapati  1 , Sanam Loghavi  2 , Jennifer Marvin-Peek  3 , Guillermo Garcia-Manero  1 , Tapan M Kadia  1 , Gautam Borthakur  1 , Naval Daver  1 , Nicholas J Short  1 , Nitin Jain  1 , Ghayas C Issa  1 , Fadi Haddad  1 , Danielle Hammond  1 , Kelly Chien  1 , Guillin Tang  2 , Beenu Thakral  2 , Guillermo Montalban-Bravo  1 , Naveen Pemmaraju  1 , Alexandre Bazinet  1 , Mahesh Swaminathan  1 , Sherry Pierce  1 , Hussein A Abbas  1 , Patrick Reville  1 , Uday Popat  4 , Elizabeth Shpall  4 , Richard Champlin  4 , Elias Jabbour  1 , Farhad Ravandi  1 , Hagop M Kantarjian  1 , Courtney D DiNardo  1
Affiliations

Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies

Jayastu Senapati et al. Am J Hematol. 2025 May.

Abstract

Ontogeny of acute myeloid leukemia (AML) provides prognostic information, however closer interrogation with respect to AML characteristics, genomics, and various treatments are warranted. We defined untreated clinical secondary (CS) AML as AML with a diagnosis of antecedent myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MDS-MPN) without exposure to hypomethylating agents or chemotherapy; genomic secondary (GS) AML included patients with myelodysplasia related cytogenetics (MRC) or myelodysplasia related mutations (MRM) without a known antecedent myeloid neoplasm or prior chemo-radiotherapy for non-myeloid neoplasms. Among newly diagnosed AML patients classified as untreated CS-AML (n = 133) or GS-AML (n = 389), median relapse-free survival (RFS) (11.9 vs. 12.4 months, p = 0.36) and overall survival (OS) (11.6 vs. 14.4 months, p = 0.75) were similar. No difference in RFS and OS between these groups treated with low-intensity therapy (LIT) and venetoclax regimens was seen, but both were inferior to de novo (DN) AML without secondary-type genomics (pure DN-AML). GS-AML defined by the presence of only MRM had superior OS compared with MRM ± MRC with LIT+ venetoclax therapy (RFS 19.5 vs. 6.8 months [p < 0.01] and OS 29.6 vs. 8.4 [p < 0.01]) and had similar RFS (29.8 months, p = 0.48) and OS (32.0 months, p = 0.48) to pure DN-AML treated with LIT+ venetoclax. On multivariate analysis in patients treated with LIT+ venetoclax, untreated CS-AML (vs. GS-AML), adverse cytogenetics and ELN 2024 adverse-risk disease (mutated TP53) were associated with higher hazard of death. Adverse cytogenetics was the strongest prognostic variable predicting survival. Mutation-driven genomic ontogeny of newly diagnosed AML with MRM appears less prognostic than cytogenetic-driven ontogeny with venetoclax-based therapy.

Keywords: Venetoclax; cytogenetics; myelodysplasia related genomics; secondary AML; stem cell transplantation.

PubMed Disclaimer

References

    1. E. Papaemmanuil, M. Gerstung, L. Bullinger, et al., “Genomic Classification and Prognosis in Acute Myeloid Leukemia,” New England Journal of Medicine 374, no. 23 (2016): 2209–2221, https://doi.org/10.1056/NEJMoa1516192.
    1. C. D. DiNardo and A. H. Wei, “How I Treat Acute Myeloid Leukemia in the Era of New Drugs,” Blood 135, no. 2 (2020): 85–96, https://doi.org/10.1182/blood.2019001239.
    1. H. Kantarjian, T. Kadia, C. DiNardo, et al., “Acute Myeloid Leukemia: Current Progress and Future Directions,” Blood Cancer Journal 11, no. 2 (2021): 41, https://doi.org/10.1038/s41408‐021‐00425‐3.
    1. C. D. DiNardo, H. P. Erba, S. D. Freeman, and A. H. Wei, “Acute Myeloid Leukaemia,” Lancet 401, no. 10393 (2023): 2073–2086. (In eng), https://doi.org/10.1016/s0140‐6736(23)00108‐3.
    1. J. Senapati, N. G. Daver, and N. Pemmaraju, “Antibody‐Drug Conjugates in Myeloid Leukemias,” Cancer Journal 28, no. 6 (2022): 454–461. (In eng), https://doi.org/10.1097/ppo.0000000000000635.

MeSH terms